QYNAPSE Inc., a medical technology company commercializing an AI-powered and proprietary neuroimaging software platform, is attending the Alzheimer’s Association International Conference 2021 (AAIC) on July 26-30, 2021 in Denver, USA and online, and will present two poster presentations on QyScore®, it’s groundbreaking neuroimaging analysis platform for both clinical routine and clinical trial settings.
QYNAPSE today announced it will present clinical data on QyScore® for Alzheimer’s disease and multiple sclerosis at the 7th Congress of the European Academy of Neurology (EAN), which is being held virtually on June 19 – 22, 2021. Enrica Cavedo, PhD, Scientific Lead at Qynapse, will give an ePresentation on June 20, 2021, at 6:05 a.m. ET and Philippe Tran, R&D Scientist at Qynapse, will give an ePoster on June 20, 2021, at 1:30 p.m. ET.
Qynapse joins the global multiple sclerosis (MS) community in recognition of World MS Day to raise awareness for everyone affected by MS. Emphasizing the World MS Day 2021 theme, MS Connections, Qynapse has been engaged for years in contributing to connect MS patients to MS research, especially in the field of neuroimaging innovation.
QYNAPSE is pleased to participate in the Sachs 4th Annual Neuroscience Innovation Forum (#Sachs_NIF) on April 28-30, 2021. Olivier Courrèges, CEO of QYNAPSE, is pleased to present QYNAPSE’s corporate vision on Day 1 of the Sachs 4th Annual Neuroscience Innovation Forum – which will be held virtually on Wednesday, April 28, 2021 at 2:20 p.m. ET.
QYNAPSE joins a historic alliance of fifty life sciences and healthcare organizations that seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research. DTRA plans to unite industry stakeholders to make clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research.
QYNAPSE is pleased to sponsor the 106th Radiology Society of North America (RSNA) Annual Meeting. This year, QYNAPSE is presenting its latest technological advancements of its QyScore® medical device and will also showcase significant developments being made with its QyPredict® AI prediction technology, which is transforming central nervous system (CNS) clinical trials.
QYNAPSE appoints Matt Ullum, CPA, MBA as Chief Commercial Officer. In his new role, Matt assumes overall responsibility for both sales and marketing to accelerate the commercialization of QYNAPSE’s solutions globally. Matt is bringing over 15 years of experience spanning the global pharmaceutical and healthcare industries with a focus on central nervous system (CNS) disorders.
QYNAPSE will present results on QyPredict®, an AI prediction technology for patient selection in Alzheimer’s clinical trials, at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) Conference. The software computes a cognitive decline risk score that can be used to enrich patient selection strategy with the aim to increase clinical trial success probability.
QYNAPSE today announces the acquisition of the Canadian company TRUE POSITIVE MEDICAL DEVICES Inc. (TPMD), a spin-off from the universities of McGill and Laval – to form the most advanced artificial intelligence (AI) platform in the field of imaging of brain diseases such as Alzheimer’s, Parkinson’s and multiple sclerosis.
Qynapse is strongly committed to innovation in the field of neurodegenerative diseases, particularly Alzheimer’s. “By combining the latest advances in neuroimaging and artificial intelligence algorithms, our solutions represent powerful tools for the diagnosis, disease monitoring and patient care for Alzheimer’s disease.”
Qynapse is a medical technology company that unlocks the potential of quantitative imaging and AI to optimize diagnosis, prognosis and longitudinal monitoring of patients with neurological diseases.
- RT @GarnierCrussard: @KrolakSalmon @ChetelatLab @QYNAPSE @IVie_HCL @HCL_research @achilleteillac #MEMORA8 days ago
- RT @GarnierCrussard: White matter hyperintensities in the splenium (not genu/body) of the corpus callosum predict cognitive decline in memo…8 days ago
- Qynapse is pleased to present clinical data demonstrating how our QyScore® #AI neuroimaging software platform helps… https://t.co/82vOHEYUPo8 days ago
- Qynapse is excited to attend the 1st Day of the #AAIC21 Conference in Denver, CO. We are proud to contribute to th… https://t.co/UiPXSpBnmk9 days ago
130, rue de Lourmel
75015 Paris – France